IBBQ vs PBE

IBBQAInvesco Nasdaq Biotechnology ETF

PBEBInvesco Biotechnology & Genome ETF

In short

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

PBE Most biotech funds own the sector by size. PBE has run a different playbook since 2005: a quant screen on momentum, quality and value that narrows the field to roughly 30 names, reshuffled every quarter.

Stated mandate

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

PBE The Fund seeks to track, before fees and expenses, the results of its designated biotechnology and genome benchmark index.

Why people hold it

• IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
• Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
• Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
• Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

• PBE The index scores biotech and genome companies on price momentum, earnings momentum, quality, management action and value, then reconstitutes quarterly, so the roster follows the scores.pionline.com
• Trading since 2005, one of the longest-running biotech ETFs on the tape, and it has stayed tight to the index it promises to follow.
• About 30 holdings, so an approval or a trial readout at one company registers in the portfolio instead of being diluted across a sprawling roster.
• Sits in the upper half of the biotech and genomics group on our review, with no structural red flags in the wrapper and a plain index mandate on file with the SEC.sec.gov

Worth knowing

• IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
• One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
• Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

• PBE 0.59% sits above the category median, and above plain index rivals like IBB at 0.44% and XBI at 0.35%. The screening model is what you pay the difference for.
• Thinly traded next to the category's heavyweights, so spreads can be wider and bigger orders need more care at the point of execution.
• A 30-stock quant portfolio can diverge sharply from the broad biotech benchmark in either direction, and it pays out only quarterly.

Full IBBQ profile⁠

Full PBE profile⁠